Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SOD1 | P00441 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3724795 | 0.82 | MAOB (0.44) | MAOBKDM4EMAPTCYP1A2GAA | |
| SCHEMBL15488959 | 0.81 | ACHE (0.52) | MAOBKDM4EGAAALDH1A1LMNA | |
| SCHEMBL19384231 | 0.81 | MAOB (0.43) | MAOBKDM4EMAPTCYP1A2GAA | |
| SCHEMBL31275767 | 0.77 | MAOB (0.46) | MAOBKDM4EMAPTCYP1A2GAA | |
| SCHEMBL4194354 | 0.77 | MAOB (0.46) | MAOBKDM4EMAPTCYP1A2GAA | |
| SCHEMBL19384488 | 0.76 | MAOB (0.50) | MAOBKDM4EMAPTALDH1A1LMNA | |
| SCHEMBL1864333 | 0.75 | CA1 (0.39) | MAOBMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL8887308 | 0.74 | MAOB (0.43) | MAOBKDM4EMAPTCYP1A2GAA | |
| SCHEMBL14157395 | 0.74 | MAOB (0.43) | MAOBKDM4EMAPTCYP1A2GAA | |
| SCHEMBL19384284 | 0.73 | LIPG (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| EP-3433254-B1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-06-17 | — | — | EP | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-18 | — | — | US | disclosed |
| EP-3433254-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| EP-3433255-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162572-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162572-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162570-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206758-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, ITGB3 | MAOB 3037/4885KDM4E 3706/4885MAPT 3675/4885 |
| US-20190112306-A1 | NAPHTHYRIDINES AS INTEGRIN ANTAGONISTS | ITGB6, ITGA6, GP6 | MAOB 3058/4885KDM4E 3675/4885MAPT 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.